Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2013 02:30 ET | Source: NeuroVive Pharmaceutical AB

NeuroVive: European phase III study approaches its final stage

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, announces that the ongoing international multicenter phase III study on the company´s drug candidate CicloMulsion® (the...
May 24, 2013 11:40 ET | Source: NeuroVive Pharmaceutical AB

NeuroVive: Interim report 1 Jan. 2013 till 31 Mar. 2013

The listing on Nasdaq OMX creates possibilities for the future “After NeuroVive’s IPO on NASDAQ OMX Stockholm Small Cap in April, the company has secured prospects for its continued work in its...
May 24, 2013 11:32 ET | Source: NeuroVive Pharmaceutical AB

NeuroVive: Delårsrapport 2013-01-01 till 2013-03-31

Noteringen på Nasdaq OMX ger förutsättningar för framtiden ”Efter vår notering av NeuroVive på NASDAQ OMX Stockholm Small Cap i april har bolaget skapat förutsättningar för det fortsatta arbetet med...
May 08, 2013 02:55 ET | Source: NeuroVive Pharmaceutical AB

NeuroVive starts Investor Relations Partnership with Laika Consulting

NeuroVive Pharmaceutical AB (publ) has initiated a collaboration within investor relations communication with Laika Consulting, a company that specializes in helping companies and other entities with...
May 08, 2013 02:55 ET | Source: NeuroVive Pharmaceutical AB

NeuroVive inleder IR-satsning med Laika Consulting

NeuroVive Pharmaceutical AB (publ) har inlett ett samarbete inom IR -kommunikation med Laika Consulting, ett företag som specialiserat sig på att hjälpa noterade bolag och finansiella aktörer med...
April 17, 2013 08:54 ET | Source: NeuroVive Pharmaceutical AB

Klargörande avseende framtida kapitalbehov

Idag den 17 april 2013 publicerade Bloomberg en intervju med VD Mikael Brönnegård. Mot bakgrund av därefter uppkomna frågor publicerar NeuroVive Pharmaceutical AB (publ) härmed ett klargörande...
April 10, 2013 02:30 ET | Source: NeuroVive Pharmaceutical AB

NeuroVive First Day of Trading on NASDAQ OMX Stockholm

Lund (Sweden) – April 10, 2013, NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, announces that its admission to NASDAQ OMX Stockholm will become effective and trading of...